TET2-mutated AML cells have defective HR due to BRCA1 and LIG4 downregulation and tolerate spontaneous and drug-induced DNA damage through PARP-1-mediated alternative NHEJ. The gene discussed is TET2; the disease is acute myeloid leukemia.